67ga gacl3

¹H NMR spectra were recorded on
a JEOL JNM-ECS 400 spectrometer (JEOL, Tokyo, Japan). Mass spectrometry
was performed using an AccuTOF LC-plus (JMS-T100LP, JEOL, Tokyo, Japan).
The analytical methods for reversed-phase HPLC (RP-HPLC) are described
in detail in the Supporting Information. Radiochemical conversions and in vitro stability
were determined by reversed-phase (RP)-TLC (Silica gel 60 RP-18 F_254S, Merck, Tokyo, Japan) developed with a mixture of 0.1%
aqueous TFA and MeCN with 0.1% TFA (2:3, v/v). [⁶⁷Ga]GaCl₃ was purchased from FUJIFILM RI Pharma (Tokyo, Japan). p-NO₂-Bn-DOTA and DOTA were purchased from Macrocyclics
(Texas, USA) and Tokyo Chemical Industry (Tokyo, Japan), respectively.
DOTA-Bn-TOC and DOTATOC were prepared from the same procedure described
previously.^{29 (link)} The syntheses of DOTAGAM^Bu, DO3AM^Bu, and p-NO₂-Bn-DO3A are described in the Supporting Information. The other chemicals obtained from the commercial sources were of
reagent grade or higher and were used without further purification.
Data for single crystal X-ray diffraction analyses were collected
on a Rigaku R-AXIS RAPID diffractometer using a graphite monochromator
with Cu Kα radiation (l = 1.54187 Å).
Data collection and reduction were performed using RAPID AUTO. The
crystallography structures were solved by direct methods using SHELXL97
and refined with SHELXL97.

[⁶⁷Ga]GaCl₃ and [⁶⁴Cu]CuCl₂ were purchased from FUJIFILM Toyama Chemical
Co., Ltd. (Tokyo, Japan). NOTA-MVK-Bzo, NOTA-MVK-Mal, and the renal
BBMVs were prepared as described previously.^{9 (link),17 (link)} The
analytical methods are described in the Supporting Information. All commercial chemicals were of analytical grade
and used without further purification.